Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful in the treatment algorithms for statin-intolerant patients with diabetes mellitus. Results of the study, which were presented at the European Society of Cardiology (ESC) Congress 2023, indicate use of bempedoic acid significantly reduced cardiovascular risk as a monotherapy, with the greatest absolute benefit observed in patients with diabetes and no adverse effect on glycemic measures observed. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more